Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
life sciences
national blog main
alnylam pharmaceuticals
boston top stories
clinical trials
drugs
boston
new york blog main
new york top stories
patisiran
rna interference
akcea therapeutics
fda
inotersen
national top stories
onpattro
san diego blog main
san diego top stories
tafamidis
hereditary transthyretin amyloidosis
pfizer
aminolevulinic acid
biotech
givosiran
new york
regeneron pharmaceuticals
san francisco blog main
san francisco top stories
vyndaqel
accelerated approval
acute hepatic porphyria
acute hepatic porphyrias
akin akinc
alirocumab
amgen
andrew fire
anylam pharmaceuticals
barry greene
boston university
What
alnylam
7
×
drug
fda
medicine
rna
pharmaceuticals
rnai
ago
interference
approved
data
medicines
new
ok
patients
second
seek
speedy
uses
afternoon
akcea
alnylam’s
amyloidosis
approval
approve
approves
attr
available
awaits
based
battle
biological
cells
cholesterol
cleared
crossed
debilitating
decades
decision
discovered
Language
Current search:
alnylam
×
@xconomy.com
4 years ago
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision